USA Biopharma Cold Storage Services Market Size, Share, Growth, Trends, and Industry Growth Analysis: By Product Type (Vaccines, Blood Products, and Medications & Biologics), Service (Consulting, Monitoring, Warehousing, Packaging, and Transportation) and Country Forecast 2020-2031

USA biopharma cold storage services market size was valued at US$ 14.2 billion in 2023 and is projected to reach US$ 26.8 billion by 2030, growing at a CAGR of 10.2% from 2024-2030. Stringent regulations by organizations like the FDA and CDC guarantee that sensitive products like vaccines, biologics, and blood products are stored at ideal conditions, stimulating demand for compliant storage.

The growing demand for biologics and specialty drugs that need to be stored at controlled temperatures also drives the demand for cold storage. Advances in technologies such as IoT-based storage equipment, AI-based predictive analytics, and novel forms of storage, such as freeze-dried biologics, are increasing efficiency, minimizing wastage, and making cold storage more economical.

In addition, the growth of clinical development and research activities, especially in precision medicine, gene therapies, and cell-based therapies, requires highly advanced storage facilities that will host these innovations. With the increase in clinical trials and growing biopharma partnerships, the need for sophisticated cold storage solutions will keep growing to enable the industry to stay abreast with future-proof industry demands while upholding product integrity.

Key Takeaways

• The U.S. biopharma cold storage services market is witnessing significant growth in the consulting segment, which was valued at US$ 0.57 billion in 2023 with a share of 4%.
• The vaccine segment is a major contributor to the cold storage market, with a share of 41.2% and was valued at US$ 5.8 Billion in 2023.

Key Developments

• In 2024, Tobin Scientific bought BioRepository Resources, increasing its biopharmaceutical storage capacity and increasing its presence in the life sciences sector. The move is strategic in that it brings more than 2 million samples into Tobin's inventory and increases its biorepository services with cutting-edge, GXP-compliant long-term storage.
• In November 2024, SciSafe was acquired by 1315 Capital, a Philadelphia-based growth equity firm specializing in healthcare. This acquisition aims to expand SciSafe's global footprint and enhance its service offerings. Founder Garrie Richardson rejoined as CEO to lead the company through this growth phase.
• In January 2023, Alcami was acquired by GHO Capital and The Vistria Group, with Ampersand Capital Partners and Alcami management retaining significant equity. This partnership aims to further enhance Alcami's growth and service offerings in the CDMO sector.

USA Biopharma Cold Storage Services Market Segmentation

Based on the product type:

• Vaccines
• Blood Products
• Medications & Biologics

The Medications & Biologics segment, valued at US$ 5.6 Billion in 2023, is projected to reach US$ 12.0 Billion by 2030 at a 12.5% CAGR. Growth is driven by advancements in biologics, personalized medicine, strict FDA regulations, and rising demand for specialized cold storage solutions for biologic therapies.

Based on the service:

• Consulting
• Monitoring
• Warehousing
• Packaging
• Transportation

The packaging segment, valued at US$ 4.82 billion in 2023, is projected to reach US$ 9.68 billion by 2030 at an 11.2% CAGR, creating a US$ 4.0 billion opportunity. Growth is driven by advanced materials, real-time temperature monitoring, and specialized solutions for high-value biologics despite material cost concerns.